A brief history of pediatric multiple sclerosis: From early observations to modern recognition

Notice: Blog posts are not subject to review by MedLink Neurology’s Editorial Board.

Author: Joaquin A Pena MD

The history of pediatric multiple sclerosis spans over a century and is marked by an evolving understanding and shifting diagnostic methods. Early progress was slowed by semantic misunderstandings, misleading interpretations, and deeply ingrained academic beliefs. For many decades, the field was shaped by initial descriptions and debates published mainly in French and German, which caused ongoing misinterpretations in later literature.

Foundations: Charcot, Pierre Marie, and Early skepticism

The foundational work of Jean-Martin Charcot (1825-1893) and his team in Paris established multiple sclerosis as a distinct disease, characterized by the classic triad of nystagmus, tremor, and slurred speech. However, Charcot himself doubted that multiple sclerosis occurred in children until his protégé, Pierre Marie (1853-1901), reported a significant series of 13 childhood-onset cases, which advanced clinical and pathological understanding of the condition. Despite these early reports, interpretation was complicated by the overlap of clinical features among various pediatric demyelinating and inherited white matter disorders.

Early observations, persistent skepticism, and mid-century renewal

Throughout the late 19th and early 20th centuries, sporadic pediatric multiple sclerosis cases were documented but often dismissed due to the prevailing belief that demyelinating symptoms in children resulted from inherited leukodystrophies. This academic inertia persisted until the mid-20th century, when studies began to clarify the clinical and pathological differences. For example, a 1958 study of 38 patients, diagnosed between 15 and 20 years of age with onset before 15, notably included eight with symptoms before age 10 and highlighted the critical need for careful differential diagnosis.

Recent decades: from rarity to recognition and collaborative progress

Over the past 10 to 20 years, pediatric multiple sclerosis has become a clearly defined clinical condition, thanks to advances in neurology, neuroimaging, and epidemiology. Collaborative groups like the International Pediatric Multiple Sclerosis Study Group (IPMSSG), founded in 2005, have sped up progress in research, consensus standards, and raising global awareness.

Recent global studies indicate that 2% to 10% of all multiple sclerosis cases now start in childhood or adolescence. Updated estimates show a crude worldwide prevalence rate of 2.53 per 100,000, with the highest rates in regions with strong pediatric neurology infrastructure. Recent reviews conclude, “there is an increase in the prevalence and incidence of pediatric multiple sclerosis (the latter to a lesser extent),” which reflects both improved diagnosis and better surveillance.

Modern advances in diagnosis

Radiological and molecular innovations. Both the revised McDonald criteria and pediatric-focused guidelines have shaped modern diagnostic standards. The 2024 updates introduce key nuances, now recognizing the optic nerve as a fifth CNS region. Advanced MRI biomarkers—such as the central vein sign, paramagnetic rim lesion, and cortical lesions—are now considered essential for improving diagnostic accuracy in both adults and children.

Detecting CSF-specific oligoclonal bands remains essential for distinguishing multiple sclerosis from mimics like MOGAD or ADEM, especially in cases with unclear imaging. Biomarker research is progressing, with serum neurofilament light chain (sNfL) and various circulating microRNAs (such as miR-320a, miR-125a-5p) now being explored for disease monitoring and personalized treatment guidance.

Differential diagnosis remains crucial. The difficulty of distinguishing pediatric multiple sclerosis from other acquired and inherited white matter disorders persists. Enhanced neuroimaging and biomarkers have allowed for earlier and more precise diagnosis, yet clinical vigilance remains essential—similar to the lessons learned from mid-20th-century case series.

Evolution in disease management

Disease-modifying therapy: off-label to evidence-based. Recent years have seen a rise in disease-modifying therapies for pediatric multiple sclerosis. These include interferons, glatiramer acetate, fumarates, teriflunomide, monoclonal antibodies such as anti-CD20 and anti-CD52, natalizumab, and fingolimod. Many are derived from adult data, with only a few formally approved for children. Real-world registry data show significant benefits from switching therapies. One large cohort found, “relapse rates were 62% lower when switching to an oral therapy and 75% lower when switching to an infusion, compared with switching to another injectable disease-modifying therapy”—directly guiding clinical decisions. Increasingly, early initiation of high-efficacy agents is considered for aggressive pediatric multiple sclerosis, though long-term safety and optimal timing are still under research. Like other areas in neurology, international collaboration speeds up evidence collection and efforts to standardize care.

Timeline of key historical and clinical milestones

Conclusions

The history of pediatric multiple sclerosis has transformed from scattered, often debated case reports into a field of ongoing research, precise diagnostics, and expanding treatment options. Though rare, pediatric multiple sclerosis shows both standard and unique features compared to adult-onset disease, affecting diagnosis, treatment, and outlook. Today’s progress—such as improved MRI biomarkers, molecular tools, and international data registries—stems directly from past debates and discoveries. However, significant gaps still exist, especially regarding long-term outcomes and personalized care for children affected. Continued collaborative research is crucial to ensure that the story of pediatric multiple sclerosis remains one of discovery, better outcomes, and hope for patients and families.

Bibliography

Abrams A, Waltz M, Casper TC, et al. switching disease-modifying therapies in pediatric multiple sclerosis: insights from real-world data. Cleveland Clinic. ConsultQD. April 28, 2023.

Charcot JM. Histologie de la sclérose en plaques. Gaz Hôp 1868; 41:554-5.

Gall JC, Hayles AB, Siekert RG, et al. Multiple sclerosis in children: a clinical study of 40 cases with onset in childhood. Pediatrics 1958;21:703-9.

Gombolay G, Johnson L, King R, et al. Worldwide epidemiology of pediatric multiple sclerosis: data from the Multiple Sclerosis International Federation Atlas of MS, third edition. J Neurol Neurosurg Psychiatr 2025;96(8):814-20. PMID 39848676

Hanefeld F. Pediatric multiple sclerosis: A short history of a long story. Neurology 2007; 68(Suppl 2): S3-S6. PMID 17438236

Isler W. Multiple Sklerose in Kindesalter. Helv Pediatr Acta 1961;16: 412-31.

Marie P. De la sclérose en plaques chez les enfants. Rev Med 1883;536.

Teleanu RI, Niculescu AG, Vladacenco OA; et al. The State of the Art of Pediatric Multiple Sclerosis. Int J Mol Sci 2023; 24(9):8251. PMID 37175954

Tenembaum S, Hartung HP. Multiple sclerosis: advances and challenges in diagnosis. Curr Opin Neurol 2025;38(3):197-204. PMID: 40145196

Walsh R, Chitnis T. Therapeutic advances in pediatric multiple sclerosis. Children (Basel) 2025;12(3):259. PMID 40150542

Yan K, Balijepalli C, Desai K; et al. Epidemiology of pediatric multiple sclerosis: a systematic literature review and meta-analysis. Mult Scler Relat Disord 2020;44:102260. PMID 32540746

Are you interested in contributing a post or becoming a guest blogger for MedLink? Contact us at editorial@medlink.com.